4 Amendments of Vladko Todorov PANAYOTOV related to 2011/2220(DEC)
Amendment 1 #
Draft opinion
Paragraph 1
Paragraph 1
1. Welcomes clearlyNotes the work of the European Medicines Agency in evaluating and supervising medicines for human and veterinary use in the Union;
Amendment 2 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Acknowledges the EMA’s willingness to publish the declarations of interests of experts involved in the evaluation of medicinal products, but deplores the fact that many of the experts have yet to publish their declarations of interests and that, when the declarations published for individual experts by the relevant national agency and by the EMA are compared, significant differences are apparent in some cases; deplores, furthermore, the fact that at least one member of the Management Board has failed to declare recent links with the pharmaceutical industry; urges the EMA accordingly to carry out detailed checks on the declarations of interests submitted to it and to implement a system under which declarations of interests are cross-checked against information held by industry and by the relevant national agencies;
Amendment 3 #
Draft opinion
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Notes that the former Executive Director of EMA wrote to the Agency on 28 December 2010 outlining the activities he was intending to take up at the end his term of office; considers the decision dated 11 January 2011 taken by the Chairman of the European Medicines Agency's (EMA) Management Board to authorize the new activities of its former Executive Director a breach of EU rules relating to conflicts of interest, in particular with regard to Title II, Article 16 of the Staff Regulations of the Officials of the European Communities; considers the fact that the Management Board adopted limitations on the future activities of the former Executive Director on 17 March 2011 - only after strong public protest - a clear proof that EMA did initially not apply the Staff Regulations properly in this high-profile case, which in turn raises serious questions about their application of the rules in general; considers that the limitations set out therein as regards the former Executive Director are not sufficient, in particular in the light of recent reports that the former Executive Director set up his new activities as early as November 2010, while he was still in office; asks the Executive Director of EMA to present a detailed report of the implementation of Article 16 of the Staff Regulations within the Agency;
Amendment 7 #
Draft opinion
Paragraph 8
Paragraph 8
8. ICalls ofn the opinion, on the basis of the data available, that discharge can be grantedAgency, therefore, to inform the discharge authority by June 2012 of the measures taken and the improvements made in respect of all these areas of concern and considers that discharge to the Executive Director of the European Medicines Agency in respect of the implementation of the Agencuthority's budget for the financial year 2010 should be postponed until the problems mentioned above have been resolved..